Categories: News

Phemex Announces Halloween Futures Trading Festival With 200,000 USDT Prize Pool

APIA, Samoa, Oct. 13, 2025 /PRNewswire/ — Phemex, the most efficient crypto exchange, announced its Halloween Futures Trading Festival, offering 200,000 USDT in rewards for traders participating between October 10 and October 31, 2025. The campaign is open to both first-time and experienced futures traders.

- Advertisement -

The festival includes:
First Futures Trade Reward — Users completing their first futures trade of 100 USDT or more receive a 200 USDT futures position voucher.
Volume-Based Milestone Pool — A 70,000 USDT reward structure distributed across five trading volume tiers.

- Advertisement -

Registration is open through October 31 at 10:00 UTC. Full details are available at the event landing page.

- Advertisement -

The festival is part of Phemex’s seasonal trading initiatives for October 2025.

- Advertisement -

About Phemex

- Advertisement -

Founded in 2019, Phemex is the most efficient crypto exchange trusted by over 6 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products that combine seamless functionality with institutional-grade security. Known for its reliability and innovative edge, Phemex stands out for prioritizing user experience and transparency in an industry where trust is essential.

- Advertisement -

For more information, please visit: https://phemex.com/

- Advertisement -

Photo – https://mma.prnewswire.com/media/2794608/1.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/phemex-announces-halloween-futures-trading-festival-with-200-000-usdt-prize-pool-302581999.html

- Advertisement -

Recent Posts

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

35 seconds ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

37 seconds ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

38 seconds ago

Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026

New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational…

39 seconds ago

LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE

Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented…

11 hours ago

EVE Energy “Mr Big” Big Battery Delivers Reliable Energy Storage Power to KLIA

KUALA LUMPUR, Malaysia, Feb. 6, 2026 /PRNewswire/ -- EVE Energy Co., Ltd. and its partners…

13 hours ago